MedTrace Logo

Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator

NCT04352335 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2020-07-02

No results posted yet for this study

Summary

The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs and recognize the effect of post-treatment NLR and overall survival in advanced lung cancer patients by retrospective review.

Conditions

Sponsors & Collaborators

  • Chung Shan Medical University

    lead OTHER

Principal Investigators

  • Shih-Ming TSAI, M.D., Ph.D. · Chung Shan Medical University

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-14
Primary Completion
2020-07-01
Completion
2020-07-01

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04352335 on ClinicalTrials.gov